Ayalew Tefferi* - Cancer Science

Author Information

Ayalew Tefferi is a distinguished researcher affiliated with the Divisions of Hematology, Departments of Internal Medicine and Laboratory Medicine at the Mayo Clinic in Rochester, MN, USA. His work primarily focuses on hematology, with significant contributions to understanding and treating various hematologic malignancies.

Research Contributions

In 2022, Ayalew Tefferi authored several impactful papers. His research covered a range of topics, including novel predictors of venous thrombosis in polycythemia vera, outcomes of pretransplant mortality prediction models in myelofibrosis, updates in chronic neutrophilic leukemia, and the classification of myeloid neoplasms. He also explored the efficacy of venetoclax combination therapy in acute myeloid leukemia and assessed cytogenetic abnormalities in essential thrombocythemia. His work is pivotal in advancing our understanding of hematologic conditions and improving treatment strategies.

Aliases

Ayalew Tefferi is also known by several aliases, including Ayalew Tefferi*, Ayale Tefferi, A Tefferi, and A. Tefferi. These variations may appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Citation Count	87,383
H-Index	146
Paper Count	1,606

Publications:

Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera

DOI: 10.1038/s41408-022-00625-5

Year: 2022

Clinical Outcomes of Pretransplant Mortality Prediction Models in Patients with Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplant

DOI: 10.1016/s2666-6367(22)00321-9

Year: 2022

Myelodysplastic/myeloproliferative neoplasms with ring sideroblasts and thrombocytosis (MDS/MPN-RS-T): Mayo-Moffitt collaborative study of 158 patients

DOI: 10.1038/s41408-022-00622-8

Year: 2022

Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management

DOI: 10.1002/ajh.26481

Year: 2022

Cardiac Events in Patients with Acute Myeloid Leukemia Treated with Venetoclax Combined with Hypomethylating Agents.

DOI: 10.1182/bloodadvances.2022007333

Year: 2022

Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach

DOI: 10.1002/ajh.26503

Year: 2022

To live is well but to live well is better: venetoclax combination therapy and quality-of-life in acute myeloid leukemia

DOI: 10.1038/s41408-022-00672-y

Year: 2022

Cytogenetic abnormalities in essential thrombocythemia: Clinical and molecular correlates and prognostic relevance in 809 informative cases

DOI: 10.1038/s41408-022-00639-z

Year: 2022

European LeukemiaNet-defined primary refractory acute myeloid leukemia: the value of allogeneic hematopoietic stem cell transplant and overall response

DOI: 10.1038/s41408-022-00606-8

Year: 2022

Real-world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts.

DOI: 10.1002/ajh.26533

Year: 2022

How are Gynecologic Cancers Diagnosed?

What Challenges Exist in Multi-Stakeholder Collaboration?

How Does iThenticate Work?

Are There Any Risks Associated with Sunscreen?

How Does Disability Insurance Work for Cancer Patients?

Which Cancers Are Most Affected by Fiber Intake?

Why is a Multidisciplinary Team Important?

How Does Cancer Affect Muscles?

How Are Participants Protected in Clinical Trials?

How Do Liquid Biopsy Kits Work?

Partnered Content Networks

Relevant Topics